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set of patients (4). Theoretically, withholding WBRT after BCS 
should be an option only for selected elderly patients with 
favorable clinical and biological prognostic factors (node 
negative, hormone sensitive, low-grade disease) and relevant 
comorbid conditions potentially affecting the life expectancy 
(5). Historically, WBRT has been delivered using conventional 
fractionation (1.8-2 Gy daily), up to a total dose of 50 Gy over 
5 weeks with a subsequent boost dose of 10-16 Gy to the 
tumor bed for a 6- to 7-week overall treatment time (1). The 
addition of a boost dose to the site of surgical excision was 
shown to further raise local control (6). Hypofractionation 
(HF) delivers a lower nominal total dose in larger and fewer 
fractions, generally over a shorter overall treatment time, 
which is an attractive option to both patients and health-care 
providers as it decreases treatment costs and increases logis-
tic convenience (7, 8). We previously reported on the long-
term results in EBC patients treated with WBRT after BCS with 
a hypofractionated schedule and a concomitant boost to the 
tumor bed (9-11). In the present paper we describe the clini-
cal results in terms of oncological outcome and toxicity profile 
of an observational study involving a selected patient popu-
lation aged >70 years treated with this treatment schedule.
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Introduction
Postoperative whole-breast radiotherapy (WBRT) sub-
sequent to breast-conserving surgery (BCS) is regarded as a 
standard of care in the multimodality management of early 
breast cancer (EBC) (1). WBRT is able to halve the average 
annual rate of disease relapse and to reduce by about a sixth 
the annual breast cancer-related death rate (2). Neverthe-
less, WBRT is quite frequently omitted and a non-negligible 
percentage of patients are treated with BCS only, especially 
in the age group of 70 to 80 years (3). This generally leads to 
a potential increase in the local recurrence rate in this sub-
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Materials and methods
Between 2005 and 2012, we submitted a consecutive series 
of 83 EBC patients to WBRT after BCS employing HF and a con-
comitant boost to the tumor bed. All patients had a minimum 
observation time of 36 months at last follow-up examination. 
Written informed consent was obtained from all patients.
Eligibility criteria
The patients to be analyzed underwent BCS for EBC and 
subsequent adjuvant WBRT and were aged >70 years at the 
time of radiation. Detailed inclusion and exclusion criteria can 
be found in Cante et al (9, 10).
Setup, simulation and target definition
Immobilization and setup were acquired with patients on 
a wing-board with their arms raised above their heads and 
radiopaque markers along the clinical borders of the breast. 
Afterwards, 5-mm slice thickness computed tomography (CT) 
was performed from the lower aspect of the mandible includ-
ing the whole thorax; an isocenter was then found in virtual 
simulation. The whole-breast clinical target volume (WB-CTV) 
encompassed the palpable breast, with superior and inferi-
or borders within the extent of the radiopaque catheters. A 
uniform limit of 5 mm divided WB-CTV from the skin surface 
and the thoracic wall. The whole-breast planning target vol-
ume (WB-PTV) was generated with the addition of a 5-mm 
isotropic margin around the WB-CTV. The lumpectomy cavity 
was defined using radiopaque clips placed at the time of sur-
gery. The concomitant-boost clinical target volume (CB-CTV) 
was generated with the addition of a 5-mm isotropic margin 
around the lumpectomy cavity, while the concomitant-boost 
planning target volume (CB-PTV) required an adjunctive mar-
gin of 5 mm. The heart was outlined as an organ at risk up 
to the level of the pulmonary trunk superiorly, with the inclu-
sion of the pericardium and the exclusion of the major ves-
sels. Both lungs were also contoured.
Treatment schedule and delivery
The treatment schedule consisted of 45 Gy to the WB-PTV 
in 20 fractions (2.25 Gy each day) delivered with 2 opposing 
6 MV tangential fields; an additional 0.25 Gy boost dose was 
concomitantly delivered daily to the CB-PTV for a total dose of 
5 Gy, using a direct 6 MV photon field. The cumulative nomi-
nal dose to the tumor bed was 50 Gy. Radiation was delivered 
either immediately after BCS (<3 months) in patients at low risk 
of distant failure, or sequentially after adjuvant chemotherapy 
in case of high-risk features. Radiobiological considerations 
and beam arrangement have been discussed elsewhere (9). 
Setup verification was done by portal images taken weekly and 
compared with digitally reconstructed radiographs obtained 
from planning CT scans.
Follow-up, toxicity and cosmesis
During follow-up, patients underwent clinical examina-
tion 3 and 6 months after the end of WBRT and twice a year 
thereafter. Surveillance for disease included a clinical exami-
nation at every time point, plain chest x-ray and mammog-
raphy once a year, complete blood cell count and serological 
markers twice a year; other radiological examinations were 
performed when needed. Acute skin toxicity was assessed at 
the completion of WBRT and after 3 months, while late skin 
toxicity was evaluated 6 months after radiotherapy. The maxi-
mum detected toxicity was scored according to the Common 
Terminology Criteria for Adverse Events, version 3.0 (12). We 
considered as skin toxicity events the following clinical cuta-
neous and subcutaneous conditions: erythema, edema, des-
quamation, ulceration, hemorrhage, necrosis, telangiectasia, 
fibrosis-induration, hyperpigmentation, retraction and atro-
phy. Cosmetic results were assessed at the end of WBRT and 
thereafter at every follow-up time point, using a physician-
rated scale consisting of different categories (excellent, good, 
fair or poor) in the comparison between the treated and un-
treated breast, as set by the Harvard criteria (13). Basically, at 
each follow-up examination, physicians were asked to judge 
the cosmetic results as follows: an ‘‘excellent’’ score was as-
signed when the treated breast looked essentially the same 
as the contralateral breast; a ‘‘good’’ score was assigned 
for minimal but identifiable radiation effects; a ‘‘fair’’ score 
meant that significant radiation effects were readily observ-
able; a ‘‘poor’’ score was used for radiation-induced severe 
late effects on the breast tissue (13).
Statistical analysis
Follow-up time was calculated as the interval between the 
end of WBRT and last follow-up examination. Disease recur-
rence was defined as local recurrence (LR) if occurring in the 
ipsilateral breast or overlying skin; as regional recurrence (RR) 
if involving the ipsilateral axillary, supraclavicular or internal 
mammary lymph nodes; and as systemic with distant metasta-
sis (DM) if arising at other sites. All LR, RR and DM were evalu-
ated to calculate the disease-free survival (DFS). Death from 
breast cancer was defined as death preceded by disease failure. 
Death from any cause was taken into account for overall sur-
vival (OS). Survival curves and actuarial rates of relapse were 
calculated using the Kaplan-Meier method. The significance of 
clinical prognostic factors with respect to both DFS and cancer-
specific survival (CSS) was assessed by the log-rank test. A p 
value <0.05 between groups was considered significant. The 
StatView software (version 5.0) was employed for the analysis.
Results
Mean follow-up time was 60 months (range 36-88). The 
baseline patient characteristics are detailed in Table I. All pa-
tients were aged >70 with an invasive primary <2 cm in diam-
eter (69%), node negative (63%), hormone sensitive (88%), 
moderately differentiated (67%) with ductal histology (64%), 
low proliferation index (64%) and no c-erbB2 amplification 
(88%). Most patients underwent quadrantectomy or lumpec-
tomy and sentinel lymph node biopsy (82%). Only 17% also 
underwent axillary dissection. Almost 88% of patients re-
ceived concomitant hormonal therapy, while 16% were given 
adjuvant chemotherapy. All patients completed the radiation 
program with no need for interruptions.
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and 2 patients had RR in the supraclavicular (1) and axillary (1) 
lymph nodes. No LR was observed by the time of last exami-
nation. Actuarial 5-year OS, CSS, DFS and local control rates 
were 92% (95% confidence interval [CI] 81.3%-96.4%), 97.5% 
(95% CI 87.6%-98.8%), 95% (95% CI 86.7%-97.3%) and 100% 
(95% CI 44.8%-100%), respectively (Figs. 1-3). The relationship 
between clinical variables and survival is outlined in Table II. 
Univariate analysis showed that Ki67 (≤20% vs. >20%; p<0.01) 
had statistically significant impact on DFS. Concerning CSS, no 
clinical variable showed any statistically significant difference.
Toxicity
The maximum acute skin toxicity was grade 0 in 57%, grade 
1 in 40% and grade 2 in 3% (Tab. III). No grade 3-4 acute skin 
toxicities were seen. Late skin and subcutaneous toxicity was 
generally mild (Tab. IV): no grade >2 events were observed. A 
grade 1 score was given to fibrosis-induration in 9% of patients, 
atrophy in 3%, telangiectasia in 2%, hyperpigmentation in 5%, 
TABLe I - Patient characteristics
Characteristic  no. (%)
Age (years)
 70-80 77 (93%)
  >80 6 (7%)
Pathological tumor stage
 pT1a 7 (8.5%)
 pT1b 10 (12%)
 pT1c 36 (43%)
 pT2 26 (31%)
Pathological nodal stage
 pN0 52 (63%)
 pN1 25 (30%)
 pNx 5 (7%)
Grade
 G1 11 (13%)
 G2 55 (67%)
 G3 17 (20%)
Estrogen receptor status
 >80% 64 (77%)
 <80% 9 (11%)
 0% 10 (12%)
Progesterone receptor status
 >80% 32 (38%)
 <80% 33 (40%)
 0% 18 (22%)
c-erbB2
 Amplification 10 (12%)
 No amplification 57 (88%)
Ki67
 <20% 52 (64%)
 20-40% 21 (26%)
 >40% 3 (5%)
 Not available 3 (5%)
Vascular invasion
 Positive 12 (14%)
 Negative 66 (79%)
 Not available 5 (7%)
Perineural invasion
 Positive 4 (5%)
 Negative 67 (81%)
 Not available 12 (14%)
Fig. 1 - Overall survival.
Fig. 2 - Cancer-specific survival.
Pattern of failure, survival and prognostic factors
The median observation time was 60 months (range 12-88). 
Six patients died: 2 of breast cancer and the remaining 4 of 
other causes. Oncological events were observed in 4 patients: 
2 patients developed DM (bone and liver: 1; lung and brain: 1) 
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Fig. 3 - Disease-free survival.
TABLe II -  Predictive factors for all-site relapse and cancer-specific 
survival
Factor Pts. Relapse P  
value 
(log rank)
BC 
death
P  
value 
(log rank)
Age (years)
 70-80 77 3 NS 2 NS
  >80 6 1 0
Tumor stage
  Tis-T1 57 2
NS
2
NS
  T2 26 2 0
Axillary status
  pN0 52 3
NS
2
NS
  pN1 31 1 0
Grade
  G1-G2 66 1
NS
1
NS
  G3 17 3 1
Hormonal 
status
  Positive 65 1
NS
1
NS
  Negative 18 3 1
HER2
  Positive 73 1
NS
0
NS
  Negative 10 3 2
Vascular  
invasion
  Positive 12 1
NS
1
NS
  Negative 71 3 1
Perineural  
invasion
  Positive 4 0
NS
0
NS
  Negative 67 4 2
Hormonal  
therapy
  Yes 10 1
NS
0
NS
  No 57 3 2
Chemotherapy
  Yes 13 1
NS
1
NS
  No 70 3 1
Axillary  
dissection
  Yes 24 0
NS
0
NS
  No 59 4 2
Ki67
  ≤20% 55 0
p<0.01
0
NS
  >20% 28 4 2
Pts. = number of patients; BC = breast cancer; NS = not significant.
and striae in 2%. A grade 2 score was observed only for fibrosis 
(3%), telangiectasia (1%) and hyperpigmentation (2%). Cos-
metic results were excellent in 69% of patients, good in 22%, 
fair in 5%, and poor in 4% (Tab. IV).
Discussion
The option of delivering a daily dose higher than 1.8-2 Gy 
with HF is quite common nowadays in WBRT after BCS for 
EBC (14). Conventionally fractionated schedules have his-
torically been the most common strategy in this context, but 
HF has been employed in several hospitals for decades and 
investigated in randomized controlled trials (8, 15). Recently, 
comprehensive guidelines drafted by the United Kingdom’s 
National Institute of Clinical Excellence (NICE) on the man-
agement of EBC recommended 40 Gy given in 15 fractions as 
the standard of care (16). The advocated advantages of HF 
have spillover effects towards patients, radiotherapy depart-
ments and health-care providers in terms of both general 
convenience and treatment costs (7). Different hypofrac-
tionated schedules have been investigated so far, with re-
sults suggesting that the α/β ratio of breast cancer may 
range between 3 and 5 Gy, close to the values of surround-
ing normal tissues (17). Hence, a mild increase in the dose 
per fraction with a slight reduction of the total dose at 
the same time may provide the same local control rate 
as conventional fractionation with no increase in toxicity as 
in  other oncological settings (18). Our retrospective data, 
even with a medium-term observation time, showed that HF 
with concomitant boost may be a viable treatment option 
for a subset of women aged >70 years with excellent onco-
logical outcome, mild toxicity and promising cosmesis. The 
optimal management of EBC in elderly women remains con-
troversial, given that most clinical trials exclude these pa-
tients from accrual. Hence, one option is to withhold WBRT 
for older patients after BCS, especially in the presence of 
low-risk features and hormone sensitivity. Nevertheless, 
some clinical data suggest that preventing local relapses and 
consequent breast-cancer-related deaths with WBRT may 
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be a valid option also in older patients. In this respect, the 
Oxford overview of randomized trials of BCS with or without 
WBRT showed a 2-fold reduction of first relapse even in 
“low-risk” older patients, although the absolute reduction in 
10-year risk of any locoregional or distant recurrence was 
lower in women ≥70 years than in younger women (8.8% vs. 
17.7%) (2). However, several trials investigated the possibil-
ity to avoid WBRT after BCS in elderly patients with low-risk 
hormone-receptor-positive breast tumors. The CALGB 9343 
trial randomized 636 women with EBC aged ≥70 years (of 
whom 55% >75 years) after BCS and adjuvant tamoxifen to 
WBRT or no WBRT. The results showed an absolute decrease 
in the ipsilateral breast tumor recurrence rate of 3% (1% vs. 
4%) at a median follow-up of 5 years and 7% (2% vs. 9%) at a 
median follow-up of 10.5 years in the radiotherapy group. 
However, no difference in OS was found between treatment 
arms (19). The recent PRIME II trial confirms these data in 
patients with <3 cm breast cancer and age >65 years, with a 
modest benefit, when WBRT was added, in terms of local 
failure reduction (1.3% vs. 4.1%; p = 0.0002) but no influ-
ence on regional recurrence, metastasis rate, contralateral 
breast cancer or OS (20). So a potential option is to avoid 
adjuvant radiation in elderly patients, especially when low-
risk features are present. The suitability of observation only, 
when the biology of the tumor is favorable, has been con-
firmed by a recent Italian multicenter randomized trial, 
which found no difference in terms of in-breast local failure 
with or without WBRT in breast cancer patients aged 55-75 
years with ≤2.5 cm tumors after modified quadrantectomy 
and adjuvant hormonal therapy (80%). After a median fol-
low-up of 108 months, the local failure rate was 3.4% with 
radiation vs. 4.4% without. OS was similar (81.4% vs. 83.7%), 
as were metastasis-free survival and breast cancer-specific 
death (21). These results confirm the viability of omitting 
WBRT for indolent breast cancer, strengthening the applica-
tion of this approach in the subset of elderly patients with 
no detrimental effects even on local control. Another option 
for this subset of patients is accelerated partial breast irra-
diation (APBI), which combines the possibility of sparing 
part of the breast tissue from irradiation with a more conve-
nient treatment schedule (22). This approach would provide 
the possibility to offer WBRT with a potential benefit in 
terms of local control also to an elderly population, with a 
more favorable logistic profile. Nevertheless, given that clin-
ical data for this treatment approach still need long-term 
confirmation, APBI should not be considered a consolidated 
clinical standard. Thus, irradiation of the whole breast still 
remains the standard approach and HF is an attractive op-
tion for WBRT in a selected elderly population. It provides an 
efficient means to improve local control and lower the sal-
vage mastectomy rate. It may represent a convenient treat-
ment option for both patient and health-care providers, de-
creasing the overall treatment costs and logistic difficulties. 
Boosting the tumor bed may further increase local control 
(17). Tumor bed boost integration within the whole-breast 
phase shortens the overall treatment time, with increased 
clinical benefit and fewer hospital visits. However, the role 
of the boost dose in an elderly population is questionable. A 
recent update of the EORTC “boost versus no boost” trial 
showed that an extra dose of 16 Gy to the tumor bed had no 
impact on OS but could improve local control, especially in 
younger patients (age <60). For older patients this benefit 
seems negligible and on average outweighed by the risk of 
moderate to severe fibrosis in the lumpectomy cavity region 
(23). Our study protocol employing HF with concomitant 
boost was drafted before the publication of mature results 
of this approach and was driven by the will to provide pa-
tients with a potential benefit in local control, with very 
TABLe III - Acute skin toxicity
Skin toxicity Grade Patients %
No change over baseline 0 47 57
Follicular, faint or dull erythema/epilation/dry desquamation/decreased sweating 1 33 40
Tender or bright erythema, patchy moist desquamation/moderate edema 2 3 3
Confluent, moist desquamation other than skin folds, pitting edema 3 0 0
Ulceration, hemorrhage, necrosis 4 0 0
TABLe IV - Late toxicity and cosmesis
Parameter Grade (%)
G1 G2 G3 G4
Fibrosis-induration 8 (9) 3 (3) 0 -
Atrophy 3 (3) 0 - -
Telangiectasia 2 (2) 1 (1) 0 -
Hyperpigmentation 4 (5) 2 (2) - -
Striae 2 (2) 0 - -
Ulceration - 0 0 0
Cosmesis
Definition Poor Fair Good Excellent
3 (4) 4 (5)  18 (22) 57 (69)
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low risk of late fibrosis due to boost integration within the 
whole breast phase, very good dose distribution, and good 
homogeneity and conformity. The toxicity associated with 
our treatment schedule was generally mild. Acute skin toxic-
ity was acceptable, with a 3% rate of G2 events and no G3-
G4 events. Late skin toxicity was generally manageable with 
a maximum 3% G1 rate for atrophy, 1% G2 rate for telangiec-
tasia, 2% G2 rate for hyperpigmentation, and 2% G1 rate for 
striae. Subcutaneous tissue toxicity consisted of a 9% G1 and 
3% G2 rate for fibrosis. These results are consistent with 
those of hypofractionated 3-week schedules: the Canadian 
trial reported a 5% G2-G3 toxicity rate for fibrosis and a 3% 
G2-G3 toxicity rate for skin toxicity at 5 years (24). The START 
B trial results at 5 years are not directly comparable because 
the normal-tissue end points were slightly different (25). 
However, WBRT can be further accelerated, as shorter treat-
ment schedules than the one we used do exist. In fact, given 
the promising results of moderate HF (dose per fraction: 
2.5-3 Gy), regimens employing highly hypofractionated 
schedules have been tested. Radiobiologically, 5 fractions of 
5.7-6 Gy are thought to be equivalent to 50 Gy in 25 frac-
tions in terms of tumor control according to the linear- 
quadratic model. The French group at the Curie Institute 
 reported on 50 elderly patients (≥70 years) treated with 
5 once-weekly fractions of 6.5 Gy delivered once a week as 
adjuvant radiation after breast conservation, with no boost 
to the lumpectomy cavity (26). At a median observation 
time of 93 months, G1-G2 induration was observed in 33% 
of patients, while no G3-G4 events were reported. The 5- 
and 7-year cause-specific survival, locoregional relapse-free 
survival and metastases-free survival were similar to those 
of patients treated with conventional fractionation (with or 
without a boost to the tumor bed). Cutuli et al (27) reported 
on women older than 70 treated with BCS followed by 
WBRT, including 133 patients submitted to HF with 32.5 Gy 
in 5 weekly fractions. The authors reported excellent locore-
gional control, with no difference compared to patients 
treated with conventional WBRT. Along these lines, the ran-
domized British FAST trial is testing HF in more than 900 EBC 
patients after BCS, comparing 5 fractions of 5.7 Gy or 6 Gy 
delivered once weekly to 50 Gy in 25 fractions in terms of 
both late toxicity and local control (28). The first results sug-
gest that 28.5 Gy given in 5 fractions may be as gentle to 
normal tissues as conventionally fractionated radiation (29). 
These data seem to be confirmed on a medium- to long-
term basis in a recent retrospective study (30). Given all this 
evidence, in our radiotherapy department, WBRT employing 
HF was proposed in routine clinical practice and found to be 
an acceptable treatment option after BCS compared with 
conventionally fractionated WBRT, as it yielded favorable 
outcome results in terms of local control, toxicity and cos-
mesis. Our study provides a single-institution experience 
with mature follow-up time, representing further proof of 
principle that HF with concurrent administration of a boost 
dose to the surgical cavity represents a safe and effective 
postoperative treatment modality with excellent results in 
elderly patients. However, several other treatment strate-
gies may be employed in this subset of patients, which are 
potentially more convenient both clinically and logistically. 
Shorter treatment schedules, no boost strategies, omission 
of WBRT after BCS, and APBI represent useful options also 
for elderly patients. The treatment choice should be based 
on tailored and personalized clinical decision-making.
Abbreviations
APBI accelerated partial breast irradiation
BCS breast-conserving surgery
CB concomitant boost
CI confidence interval
CSS cancer-specific survival
CT computed tomography
CTV clinical target volume
DFS disease-free survival
DM distant metastasis
EBC early breast cancer
HF hypofractionation
LR local recurrence
OS overall survival
PTV planning target volume
RR regional recurrence
WB whole breast
WBRT whole-breast radiotherapy
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